Rosemont to buy Aytu BioPharma at $2.70 a share, a 51.7% premium
What's the deal? Rosemont PharmaceuticalsDealroom has a profile for this one. Try Dealroom → has agreed to acquire US specialty drugmaker Aytu BioPharma in an all-cash tender offer of $2.70 per share. The deal, announced November 16, 2026, values each share at a 51.7% premium to Aytu's November 13 closing price and a 41.1% premium to its 30-day volume-weighted average price.
How it works: A Rosemont subsidiary will launch a tender offer for all outstanding Aytu shares, followed by a second-step merger at the same price. The offer requires a majority of shares to be tendered; closing is expected by the end of December 2026.
Aytu's board unanimously approved the agreement. Investors including Nantahala Capital ManagementDealroom has a profile for this one. Try Dealroom → and Stonepine Capital ManagementDealroom has a profile for this one. Try Dealroom →, plus Aytu's directors and officers, have signed support agreements to tender their shares.
What each side does: Denver-based Aytu develops medicines for central nervous system (CNS) diseases, with an adult and pediatric specialty portfolio. Rosemont, based in Greenville, South Carolina, and Leeds, UK, is a global specialty pharmaceutical company.
Why now? Aytu's legacy portfolio has weakened. Fiscal 2026 revenue fell 13% to $57.6 million, and the company posted a $14.3 million net loss. EXXUA, its newly launched depression drug, contributed $6.6 million in its first fiscal year but did not lift full-year adjusted EBITDA into positive territory.
What they're saying: Rosemont CEO Alok Sonig called the deal "an important step in Rosemont's US growth strategy." Aytu CEO Josh Disbrow said the transaction "delivers compelling value to our shareholders."
The signal: The deal marks an exit for a small CNS specialty drugmaker struggling to turn a new launch into profit, and a US foothold for a UK-rooted buyer. For shareholders, the premium offers a cash exit after a year of falling revenue and losses.
Read more: streetinsider.com
Image credit: "ClearRx prescription bottles" by bartsz, licensed under CC BY 2.0